The Retinoic Acid Receptor Gamma pipeline drugs market research report outlays comprehensive information on the Retinoic Acid Receptor Gamma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Retinoic Acid Receptor Gamma pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Dermatology, Musculoskeletal Disorders, Respiratory, and Oncology which include the indications Acne Vulgaris, Hand Dermatitis, Musculoskeletal Disorders, Fibrosis, Bronchopulmonary Dysplasia, Idiopathic Pulmonary Fibrosis, Head And Neck Cancer, and Non-Small Cell Lung Cancer. It also reviews key players involved in Retinoic Acid Receptor Gamma targeted therapeutics development with respective active and dormant or discontinued products.

The Retinoic Acid Receptor Gamma pipeline targets constitutes close to 20 molecules. Out of which, approximately 20 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 4, 1, 2, 3, 1, 7, and 1 respectively.

Retinoic Acid Receptor Gamma overview

Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

For a complete picture of Retinoic Acid Receptor Gamma’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.